Gina Chapman, CARGO Therapeutics CEO

Cell ther­a­py biotech from Stan­ford CAR-T leader Crys­tal Mack­all nabs $200M for PhII 

A biotech born out of the work of Stan­ford CAR-T leader Crys­tal Mack­all is pub­licly un­veil­ing its $200 mil­lion Se­ries A Wednes­day, af­ter al­ready go­ing through a Phase I clin­i­cal tri­al, re­brand­ing and set­ting up plans for a po­ten­tial reg­is­tra­tional study.

CAR­GO Ther­a­peu­tics will en­ter a Phase II tri­al lat­er this year with the goal of tak­ing its au­tol­o­gous CD22-tar­get­ed CAR-T cell ther­a­py to the FDA’s doorsteps for an ap­proval in large B-cell lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.